Alcon strengthens leadership in IOL innovation with launch of Clareon Presbyopia

New Delhi: Alcon, the global leader in eye care, has announced the launch of the Clareon® Family of intraocular lenses (IOLs) in India.

Utilizing Alcon’s most advanced IOL material in its 20+ years of IOL innovation, Clareon delivers consistent visual outcomes and exceptional clarity that lasts.

Clareon’s clarity is born out of a glistening-free^§ IOL material that has among the lowest levels of haze and subsurface nanoglistenings (SSNGs), compared to leading competitor IOLs.

The Clareon platform is available in India in two PCIOL technologies:

• Clareon PanOptix, which delivers exceptional clarity and offers spectacle independence across all distances with a patient satisfaction rate of 99.2%

• PanOptix® Trifocal IOL, implanted over 2.2 million** times, making it the most widely implanted trifocal IOL in the world

• Clareon Vivity with wavefront-shaping X- WAVE™ technology, offering clinically proven exceptionally low rate of visual disturbances and unsurpassed clarity. 9 in 10 (90%) patients were satisfied with their visual outcome and said they would choose Clareon Vivity IOL again for themselves and recommend it for friends and family

• Vivity® IOL, designed to extend vision and simplify the presbyopia-correcting experience for surgeons and patients while delivering monofocal- like certainty

“We are proud to offer the full range of our latest IOL technology to patients in India. At Alcon, we are consistently pushing the boundaries to deliver transformational innovation to cataract surgeons and their patients,” said Amar Vyas, Country Head of Alcon India.

“Clareon builds on Alcon’s long legacy of IOL innovation and is the result of robust R&D efforts at every level—inventive material science, advanced manufacturing techniques and novel delivery systems. Our most advanced platform to date, Clareon delivers exceptional, long-lasting clarity.”

The Clareon portfolio leverages many of the same design characteristics and optics as Alcon’s leading IOLs to help deliver the outcomes surgeons expect.  Clareon IOLs offer sharp, crisp vision with a proprietary edge designed to help reduce glare and posterior capsular opacification. The lens’ unique and proven STABLEFORCE^® Haptics provide superior axial and rotational stability.  Clareon IOLs have been extensively researched, with inclusions in 30 published studies worldwide.

Clareon IOLs are inserted using the next-generation, reusable Clareon Monarch^® IV Delivery System, which provides precise and controlled implantation and that was designed specifically for the new Clareon material.

More than 28 million cataract surgeries are performed each year in the world. With the aging population and increased life expectancies, these surgeries are expected to increase 3-4% per year for the next 30 years, leading to an estimated 60 million global cataract surgeries annually by 2045.

“As one of the early adopters of Clareon IOLs, I am impressed with the clarity of the new IOL material, delivery system and consistent refractive outcomes,” said Dr Shail Vasavada. “I’m excited about the possibilities I can offer my patients with confidence, given the high rate of patient satisfaction.”

Clareon PanOptix offers patients the possibility of 20/20 vision at distance (far), intermediate (at arm’s length) and near (up close), with continuous vision of 20/25 or better. PanOptix is the most implanted trifocal lOL worldwide and delivers an exceptional high-quality visual experience from far to near, with 99% patient satisfaction. PanOptix has been implanted over 2.2 million times, with more than 9 out of 10 patients being completely spectacle-free at all distances.

Clareon Vivity is an extended depth of focus lens with wavefront-shaping X-WAVE™ technology, delivering monofocal-quality distance with excellent intermediate and functional near vision and a monofocal visual disturbance profile. Vivity provides surgeons with an alternative option for cataract patients who may not be eligible for a diffractive IOL but are seeking presbyopia correction during surgery.